Connect with us

Hi, what are you looking for?

Jewish Business News

Financial Research

Why Jim Cramer Is Staying Away from Biotechs

Jim Cramer

Jim Cramer on his CNBC Mad Money program was bullish on biotechs all summer. This was after a surplus of biotech IPOs flooded the market in the spring, and the sector bottomed. Biotechs rebounded with a vengeance all summer, and Jim Cramer was pushing the sector, even, at one point, making fun of Fed Chief Janet Yellen for warning the public that biotechs were overvalued.

Jim Cramer got behind biotechs that has innovative ways of treating rare conditions, or producing so-called “orphan drugs.” These orphan drugs carry a high price tag, because the conditions they treat are rare and often deadly, and there are high barriers to competition.

Mad Money often featured Cramers “Four Horsemen of Biotech” Regeneron, Gilead, Celgene and Biogen Idec. However, one of these four horsemen, Gilead, faltered the other day when data came out for a new Hepatitis C treatment from competitor AbbVie. The defense against competition, which Warren Buffett refers to as a company’s “moat” didn’t seem to hold up in the case of Gilead. On news of competition, other biotechs sold off, and Cramer is sensing a bearish sentiment on the sector and would hold off buying for now.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış